Short answer
Corvus Pharmaceuticals, Inc. (CRVS) filed an 8-K current report with the SEC on July 22, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Ian T. Clark resigning from Corvus Pharmaceuticals’ board effective July 22, 2026.
Corvus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Ian T. Clark resigning from Corvus Pharmaceuticals’ board effective July 22, 2026
- Departure follows over nine years of board service
- Board composition change without disclosed successor or stated disagreement
- Investor focus: potential impact on governance continuity and strategic oversight
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Corvus Pharmaceuticals, Inc. 8-K filings
Get the next CRVS 8-K as it lands
Follow CRVS for push alerts, or ask the research agent what this filing means.